Claims
- 1. (S)-7-[(4,4′-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid, hydrochloride.
- 2. The compound of claim 1 having a melting point of about 291° C.
- 3. The compound of claim 1 having a negative specific rotation of about 175.
- 4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- 5. A process for preparing the compound of claim 1 which comprises forming a solution of (S)-7-[(4,4′-bipiperidin-1-yl)carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid, hydrochloride and crystallizing said hydrochloride salt by precipitation or recrystallization.
- 6. A method of inhibiting platelet aggregration which comprises administering the compound of claim 1 to a mammal in need thereof.
- 7. A method of treating myocardial infarction, thrombosis, embolism, stroke and infarct-related disorders, or restenosis following angioplasty, which comprises administering the compound of claim 1.
- 8. A method for inhibiting the reocclusion or restenosis of an artery or vein following fibrinolytic therapy, which comprises internal administration of a compound according to claim 1 and a fibrinolytic agent.
- 9. A method for inhibiting platelet aggregation comprising administering a compound according to claim 1, and a cyclooxygenase inhibitor, a thromobxane synthesis inhibitor, a thromboxane antagonist, a heparin, a thrombin inhibitor, an ADP inhibitor.
- 10. A method for inhibiting platelet aggregation comprising administering a compound according to claim 1 and aspirin, ticlopidine, warfarin or clopidogrel.
- 11. A method according to claim 6 for treating or preventing myocardial infarction.
- 12. A method according to claim 6 for treating or preventing unstable angina.
- 13. A method according to claim 6 for treating or preventing transient ischemia attack.
- 14. A method according to claim 6 for treating or preventing stroke.
- 15. A method according to claim 6 for preventing restenosis of an artery or vein following angioplasty.
- 16. A method for inhibiting platelet aggregation comprising administering a compound according to claim 1 and aspirin.
- 17. A pharmaceutical composition according to claim 4 comprising a 20 mg unit dose.
Parent Case Info
This application claims benefit of provisional application Ser. No. 60/025,369 filed Sep. 3, 1996. This application is a 371 of PCT/US97/15292 filed Aug. 29, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US97/15292 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/09629 |
3/12/1998 |
WO |
A |
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5693636 |
Bondinell et al. |
Dec 1997 |
A |
5939412 |
Bondinell et al. |
Aug 1999 |
A |
Foreign Referenced Citations (4)
Number |
Date |
Country |
WO 9300095 |
Jan 1993 |
WO |
WO 9414776 |
Jul 1994 |
WO |
WO 9518619 |
Jul 1995 |
WO |
WO9518619 |
Jul 1995 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/025369 |
Sep 1996 |
US |